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Myotonic dystrophy (DM) is commonly associated with CTG repeat expansions within 
the gene for DM-protein kinase (DMPK). The effect of altered expression levels of DMPK, 
which is ubiquitously expressed in all muscle cell lineages during development, was 
examined by disrupting the endogenous Dmpk gene and overexpressing a normal 
human DMPK transgene in mice. Nullizygous (-/-) mice showed only inconsistent and 
minor size changes in head and neck muscle fibres at older age, animals with the highest 
DMPK transgene expression showed hypertrophic cardiomyopathy and enhanced 
neonatal mortality. However, both models lack other frequent DM symptoms including 
the fibre-type dependent atrophy, myotonia, cataract and male-infertility. These results 
strengthen the contention that simple loss- or gain-of-expression of DMPK is not the 
only crucial requirement for development of the disease.
Myotonic dystrophy (DM) is one of the most prevalent 
trinucleotide-repeat amplification disorders with a 
highly complex and variable pattern of progressive 
weakness and wasting of muscle, myotonia, cardiac 
conduction defects, smooth muscle involvement, men­
tal retardation, hypersomnia, ocular cataracts, testicu­
lar atrophy or endocrine disfunction1. The age at onset 
and the severeness of disease expression, especially the 
progressive wasting of muscles, is correlated to the 
length of expansion of an unstable (CTG)n trinu­
cleotide repeat in 19ql3.3 (refs 2-8). Among the now 
known dynamic trinucleotide repeat diseases, the 
expanding DNA-motif in DM is unique in that it forms 
the largest repeats and is located in the 3' UTR of a gene 
that encode isoforms of a serine/threonine protein 
kinase (DMPK) with distinct properties2"4,9“11. 
Although we know that mitotic somatic events and 
ageing, in addition to germ line variation, contribute 
substantially to intergenerational and intra-individual 
CTG-length mosaicism within this gene12,13 it is still an 
open question whether the expanded repeat influences 
the gene (chromatin domain alterations), its RNA or its 
protein products (interference with transcription, alter­
native splicing, transport, stability or translational effi­
ciency of mRNA), or the entire cellular context in 
which DMPKs are expressed11. Unfortunately, quan­
titation of DMPK mRNA and protein levels in DM 
patient material has yielded contradictory results14^ 18 
and did not yet add to our knowledge of the mecha­
nisms involved. To gain further insight into the normal 
biological role of DMPK m á  its involvement in disease 
manifestation we studied the effects of altered expres­
sion levels in mouse models.
Distribution of Dmpk mRNA during development
To identify cell lineages that could potentially be 
affected by abnormal expression of the Dmpk gene we 
performed RNA in situ hybridization (ISH) on whole 
mount preparations and body sections of mouse 
embryos. At embryonic day 10.5 (e l0.5) Dmpk RNA is 
already present and shows a specific and symmetric 
segmental expression pattern at both sites along the 
rostro-caudal axis of the neural tube (Fig. 1 «,/;), in 
somites, where expression is restricted to the myotome 
region that consists of only few cells medial from the 
dermatome. During midgestation (e l4.5) expression 
of Dmpk is visible within all smooth and striated mus­
cle cells (such as, the gut, tongue, oesophagus, 
diaphragm and intercostal muscles). At e l8.5 (Fig. I 
d,e), Dmpk is expressed at high levels in smooth mus­
cle cells of the stomach, gut and bladder, but also in 
striated muscle cells of the vibrissae, esophagus, and 
intercostal muscles. By this developmental stage, the 
expression in card io myocytes has also become much 
more prominent. Expression in all muscle groups 
remained high during neonatal life and maturation. 
Onset of expression in brain is late; hybridizations to 
frontal sections of the head of embryos or a two-day- 
old neonatal mouse revealed no significant signal 
intensities in any of the regions of the CNS. At 14 days 
of age we found expression in the retina, the granular 
layer of the cerebellum, and in the dentate gyrus and 
pyramidal cells of the hippocampus. Within all other 
tissues, including the gonads, Dmpk mRNA was only 
identified in interstitial cells, smooth muscle or 
myoepithelial cells surrounding tubuli or vasculature. 
Taken together, these Dmpk mRNA distribution pat-
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op ECG abnormalities, arrythmias, mitral valve pro­
lapse or congestive heart failure and sudden death is 
not an uncommon manifestation of DM 1,31,32. Unlike 
this situation, in the hearts of our mice we did not 
observe significant changes due to fatty infiltrations 
or fibrosis in the conductive system, nor could we 
detect conspicuous changes in the distribution of a -  
and ß-cardiac MHC isoforms, but further longitudi­
nal examinations during the last period of the animals 
life span are warranted. Although the hearts from the 
transgenic mice were easily identified by their irregu­
lar, bulbous appearance, no significant deviations in 
wet or dry heart weight, ECG recordings or left ven­
tricular pressure measurements (recorded from isolat­
ed hearts, which were perfused33) were noticed. The 
absence of ECG changes is in agreement with the rela­
tively unaffected conductive system of the hearts in 
Tg26 and TgI5.
Conclusion
We have exploited the mouse as a study model for 
DMPK  function in normal and pathological situa­
tions. First, we demonstrated that expression of Dmpk 
mRNA starts early in (mouse) development, around 
the earliest phases of myogenesis. Subsequently the 
gene is switched on in all 
striated muscles and in 
smooth muscles linings 
surrounding hollow 
organs, vasculature and 
secretory ducts of 
glands. Onset of expres­
sion is rather late, 
between el4.5 and el8.5, 
in cardiac muscles. As 
the ISH data cover fairly 
accurately the cruder 
picture for expression- 
distribution in human 
tissues2,9, and because 
the DMPK  genes are highly similar in man and 
mouse9,34, we may assume that both the early and late 
function (if any) of DMPK  is conserved. Gene target­
ing in ES cells and conventional transgenesis with a 
DMPK  containing genome segment was thus con­
sidered a feasible approach to mimic putative scenar- 
ios i 1 »35,36 fo r  over_ anc¡ underexpression of the protein 
in patients. Still, a point of major concern in these 
studies is that the syntenic DMPK  genome area of 
man and mouse contains an exceptionally high density 
of genes, some of which have overlap in museie-spe- 
cific expression9,21,37. We anticipated that this could 
complicate knock out studies, as both the nature and 
the exact location of resistance-cassettes may become 
determinants in the effects on neighbouring genes 
and thus, on phenotypic expression in the mutant 
mice. Indeed mRNA transcripts from the upstream 
Dmvn9 gene are altered by downstream insertion of 
the HygroB cassette (Fig. 2c), illustrating this point. It 
was therefore most suprising that the effects of the 
nullizygous replacement mutation in the Dmpk 
homologue are extremely mild, during all phases of 
mouse development and ageing. The marginally 
altered fibre sizes but otherwise normal appearance 
and fibre-type distributions in only sterno- and
cleidocephalic muscles in knock-out mutants, and the 
preliminary findings on altered Ca2'1' homeostasis in 
(hind leg derived) myotubes cultured in vitro (data 
not shown) were the only phenotypic features that 
emerged. Likewise, the evident transgene copy-num- 
ber dependent cardiomyopathy and spurious physio­
logical problems, were the only histological 
abnormalities in the overexpressor model. Although 
careful longitudinal monitoring during the last quad­
rant of life, in depth physiological and spatial / con­
textual memory analyses still have to be performed, 
we may conclude that the following prominent fea­
tures of DM manifestation in patients are lacking in 
our models: (i) no evident neonatal (respiratory) 
problems were seen, (ii) Once apparent, none of the 
histopathologicai conditions was further progressively 
worsening during ageing, over a 18 months life span, 
(iii) Signs of myotonia were never observed, (iv)There 
were no abnormalities like ringed fibres, fibres with 
central nuclei, or fibre splitting and (immaturity) in 
muscle spindles in tongue, neck, foreleg, gastroc­
nemius or diaphragm, (v) Importantly, we found no 
shifts in fibre type distribution (myosin ATPase stain­
ing), not even when assayed for changes in content of 
fetal myosin by direct immunohistological
procedures38. Also the lev­
els of MyoD mRNA in 
these muscles, one of the 
most sensitive criteria for 
the read-out of regenera­
tive events39, did not fluc­
tuate more than a factor 
1-1,5 as assayed by n o rth ­
ern blotting (not shown), 
(vi) The gross m o r­
phological changes in 
heart of Tg26 and Tgl5  
animals are not an entirely 
faithful reflection of the 
replacement of myocar­
dium and conductive system by fatty infiltration and 
fibrosis and the ECG abnormalities in human DM 
patients1,3Ü~32. (vii) Male sterility or breeding p rob­
lems were not encountered, and (viii) lens opacities 
were not seen. In view of the apparent discrepancy in 
phenotypic complexity and severity during the 
neonatal and adult periods of life in our mice and in 
human patients, the question remains whether the 
rather simplified models for under- and overexpres­
sion of DMPK could in fact be expected to reflect the 
multisystemic effects of CTG-repeat expansion11. For 
comparison, it is important to note that the manifes­
tation of many of these symptoms in patients is not 
always well correlated to the extent of CTG-repeat 
expansion8. On the other hand, the alterations in 
DMPK  product levels reported for patients that do 
have a clear manifestation of pathology14-18, are much 
more subtle in nature than in our models, where the 
levels of DMPK protein that could be attained range 
between 0-10-fold of normal. Still, for skele tal muscle 
(features i-v, above) there are many possibilities to 
explain the mild pathology. Compared to muscles in 
human patients, mouse muscles may respond dif­
ferently in degeneration-regeneration processes (as 
seen in the Mdx model40) or there may be redundant
Table 2 Electrophysiological characteristics of 
neuromuscular junctions of Tg26 and wild-type mice
Tg 26 Wild type
MEPP amplitude (mV) 1.00 ±0.04 0.93 ± 0.03
MEPP frequency (s"1) 1.17 ± 0.15 1.17 ± 0.17
EPP amplitude (mV) 32 ±1.0 31 ±0.9
Quantal content 51 ±1.2 53 ±2.1
Measurements were done on diaphragms of three (two females 
and one male) Tg26 and wild-type mice each. Values are the 
grand mean ± S.E.M of the muscle means. Fifteen endplates 
were sampled per muscle. There were no statistically significant 
differences between the means of the Tg26 and wifd-type 
group. Abbreviations: MEPP, miniature endplate potential; EPP, 
endplate potential.
pathways in the mouse not present in the human. We 
formally also cannot exclude that we overlooked fibre 
malfunction because the system might have been 
insufficiently challenged by the minute workload (due 
to small body size) under normal laboratory housing 
conditions. Finally, although less likely, there is the 
possibility that intracellular adaptations or 
reprogramming of cell lineages occuring at an early 
time point in development help in masking the effects 
of germ-line mutation in our models. We have recent­
ly observed such effects in mice that are deficient in 
creatine kinases41. In contrast, in patients the graded 
CTG-repeat expansion could yield dominance more 
slowly (as with somatic mutations) and challenge the 
system only after the situation in muscle differentia­
tion is permanently fixed. Whatever the situation in 
muscle may be, the fact that the mere gain or loss of 
DMPK expression in our models does not evoke any 
of the other DM~assodated pathogenic effects, 
including the muitisystemic congenital problems, the 
male sterility and cataracts are more difficult to com­
prehend. The most straightforward interpretation of 
our results is that the dominant (CTG)n repeat expan­
sion is a disease evoking abnormality, not coupled to 
DMPK  dosage effects only. Unless multiple differences 
between species are invoked this may imply that 
besides the DMPK  gene, more candidate genes, such 
as those encoding for the Dmrn9 WD-rep eat pro­
tein19 and DMAHP (DM associated homeobox pro­
tein)21, may be involved in disease manifestation. In 
addition, the greater CTG-repeat lengths could titrate 
ubiquitous cellular DNA or RNA binding proteins or 
affect cell cycle progression in a direct way, in patterns 
not obligatory overlapping with the DMPK tissue-dis­
tribution. Perhaps much more useful for future 
fundamental studies and for the development of 
therapeutic modalities, therefore, might be the mice 
with expanding CTG-repeat mutations and a hum an­
ized Dmpk 3' UTR exon. Construction of such mutant 
mice has become feasible by improvements in gene 
targeting strategies and is in progress.
In conclusion, our mouse models do not resolve 
which pathway for CTG-repeat induced DMPK  
expression distortion11 is involved in disease aetiology, 
however they are useful in the study of the biological 
role of DMPK  Studies of in vitro cultivated myoblasts 
and myotubes of Dmpk-I-  mice are yielding insight 
into the relation between Dmpk activity and depolari­
sation triggered ion-release events (P.J.T.A.G. and A. 
Benders, in preparation). We expect cultured 
myoblasts and cardiomyocytes from our T26 animals 
to provide complementary understanding of the nor­
mal biological relevance of DMPK. Finally, the ovevex- 
pressor mice offer us a valuable new system to follow 
the development of cardiac myopathy and provide an 
easily accessible system for studies of human Dmpk 
mRNA splicing and transport, and the identification 
of DMPK partners and phosphorylation substrates in 
different cell types.
Methods
Construction of the targeting vector. The targeting vector 
pDMHyTK was derived from a mouse strain 129 cosmid 
mDMRc8 9. A 9.8-kb Dmrn9/Dmpk gene segment served as 
basis for the construct Two adjacent BamHl fragments,
including the ATG translation start and 10 of the 11 conserved 
kinase domains, spanning 4.5 kb, were replaced by a BcimHi- 
%/II-hygroB cassette42. Furthermore a 2,0-kb Bglll-BamHl- 
HSV-tk cassette was attached to the 5' side of the vector as an 
anti-selectable tag. E14 ES cells were maintained as 
described'11,42.
Transfection and selection of ES cells. ES cells (107) were 
mixed in serum free medium with targeting vector DNA (25 
jig/ml) linearized at the 3' end (Hmdlll) and electroporated at 
250 V and 500 pF using a Gene Puiser (Bio Rad) apparatus. 
Cells were seeded onto SNLH9 feeder cells and positive-nega­
tive selection was started after 24 h with 250 Jig/ml 
hygromycinB (ICN) and 0.2 |aM F1AU (a kind gift of Bristol 
Myers), Cell colonies were picked after 10 days of selection and 
screened by routine Southern blot analysis with 5' and 3' 
probes that flank the sequences present in the targeting vector 
(Fig. 1). ES cells resulting from genuine homologous recombi­
nation events (frequency 2.5%) were karyotyped and ap­
proximately 8-12 cells of each clone were microinjecled into 
blastocysts and implanted into pseudopregnant C57BL/6 foster 
mothers41,43.
Generation and identification of chimaeric and heterozy­
gous/homozygous mice. Institutional review board approval 
for the mouse experiments was obtained at the University of 
Nijmegen and the Netherlands Cancer Institute. Anesthesia 
was performed by administration of 2,2,2-tribromoethanol 
(0,2 mg/body weight). Five highly chimaeric male mice of lines 
A15, A20 and A33 were bred with C57BL/6 females. Three A33 
males gave 12, 32 and 35% agouti offspring. Only one A15 chi­
maera gave agouti pups (9%). Genomic tail DNAs were pre­
pared as described44, and screened by PCR or Southern blot 
analysis. PCR was performed with sense- primer I 
(5’-GCAAGTTTGGGGAGCGGAT-3\ located in Dmpk exon 
5), anti-sense primer II ( 5 ' - G A AT GAG G TCCTG AG CTT-31, 
located in Dmpk exon 8) and sense- primer III (5-GGCT- 
GGCACTCTGTCGATACCC-3', located in the hygroB cas­
sette). Genomic DNA (100 ng) was PCR amplified with 100 ng 
of each primer by a standard protocol and 30 cycles of 94 °C 
for 1 min, 60 °C for 1 min, and 72 °C for 3 min. The presence 
of the wild-type and/or mutated alleles was demonstrated by 
amplification of a l.l-kb fragment with primers I and II, 
and/or a 0.5-kb fragment with primers III and II, respectively.
Generation of mice carrying human DMPK  transgenes.
Transgenic mice of strain FVB were generated by microinjec­
tion of the agarose purified NheI fragment isolated from cos- 
mid clone Yal0026345 into one-cell embryos following routine 
procedures. Positive transgenic mice were identified by PCR 
and Southern blot analysis on genomic tail DNA as for DM 
disease diagnosis4. Genomic Southern blots of BamHl,  EcoRI, 
or H///dIII digested tail DNA were probed with three human 
specific probes: (A) a genomic 0.3-kb ik/z/HI-NcoI fragment 
located in the last intron of Dmrn9 (ref. 19) to identify the 5' 
end of the construct; (B) a genomic 2.6-kb BamHl fragment 
containing exons 4-8; (C) a genomic 1.5-kb EcoRl-HindlU 
fragment overlapping with the 3' end of the transgene34.
RNA analysis. RNAs were purified, resolved on l.2%/2.2 M 
agarose-formaldehyde gels and analysed by northern blot 
analysis (10 jLig RNA per lane) according to standard proce­
dures. Blots containing RNAs from knock-out mutants and 
controls were probed with a complete mouse Dmpk cDNA 
clone B15 (ref, 9), a 1.3-kb Pst\ glyceraldehyde-3-phosphate 
dehydrogenase (GAPDFÏ) cDNA probe, a 2.2-kb Salì 
hygromycineB {Hygro) cDNA probe, and with 0.8-kb 
EcoRllXhal and 1.2-kbp Xhol fragments of mouse Dmni9  
cDNA9,19.
Whole mount RNA in situ hybridization (ISH), Embryos
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were fixed overnight in 4% paraformaldehyde in PBS at 4 °C. 
For hybridization the probe DMR-B15, including 2,6-kb of the 
mouse Dmpk cDNA9,34, cloned into pBlueSK was used. Digoxi- 
genin labelled "antisense” and “sense” RNA probes were 
derived from the 2,6-kb DMR-B15 cDNA insert9 after lineari­
sation of the plasmid with EcoRl or Xhol, and RNA in vitro 
transcription with T7 or T3 RNA polymerases in presence of 
DIG-UTP. Whole mount RNA in situ hybridization on day 
10.5 embryos was performed following standard protocols46,47. 
Probe detection was done using a preabsorbed an- 
ti-DlG-alkaline phosphatase antibody and staining with NBT 
and X-phosphate (protocol Bo eh ringer Mannheim GmbH). 
The embryos were stored in PBT with 1 mM EDTA and 
analysed. For detailed analysis the embryos were cryosec- 
tioned, and counterstained with 1 % eosin. For ÍSH on el4.5, 
e l8.5 embryos and newborn mice tissue sections tissue sam­
ples were prepared for cryostat sectioning as described48. Sec­
tions (10 jam) were mounted on 3-aminopropyltriethoxysilane 
coated slides. Sense and anti-sense Dmpk B15 RNA probes 
were labelled with a 35S-UTP to a specific activity of >109 
dpm/|ig and probe length was reduced to 150-200 nucleotides 
by alkaline hydrolysis. All other experimental conditions were 
as described48. Slides were coated with Ilford K5 photoemul­
sion for autoradiography, 2-3 weeks exposed at 4 °C, devel­
oped in Kodak D19b and stained with Giemsa. All 
preparations were analysed with bright- and dark-fìeld 
illumination with a Zeiss SV8 stereomicroscope or a Zeiss 
Axiophot microscope.
Protein and western blot analysis. Polyclonal aDMK anti­
serum directed against recombinant DMPK protein, encoded 
by exons 11 and 12, was a kind gift of Dr. R.G. Korneluk, 
Ottawa, Canada23. For western blot analysis, tissue samples 
were homogenized in 10 mM Tris-pH 7.5/1 mM EDTA buffer 
containing 1% SDS, 1 mM PMSF and 0.1% of a protease 
inhibitor stock solution (leupeptin 1.1 mg/ml, benzamidin 
15.7 mg/ml, aprotein 2 mg/ml, bacitrin 1 mg/ml, pepstatin 2 
mg/ml), run on a 10% SDS-poIyacrylamide gels and trans­
ferred to nitrocellulose using standard procedures. Blots con­
taining tissue extracts were blocked with 5% milk powder in 
phosphate-buffered saline, 0.05% Tween-20 (PBST), incubated 
with aDMK or anti-DM/pep2 antiserum in a 1:1000 or 1:750 
dilution in PBST, respectively, washed and subsequently incu­
bated with peroxidase-conjuga ted swine-anti-rabbit immuno- 
globin (Dakopatts). After washing the blots were developed 
using the chemiluminescence western blotting reagent (Boe- 
h r i nger- M a n n he i m ).
Immunohistochemistry. Serial cryostat sections (8 Jim, cover­
ing a 500 p,m segment) of muscles of the neck region of 
homozygous null mutant mice and age-matched wild-type 
mice were incubated with monoclonal antibodies displaying 
differential reactivities with MHC isoforms38, Incubations 
were performed in a humid chamber according to standard 
procedures using peroxidase-conjugated rabbit-anti-mouse 
immunoglobulin (Dakopatts) as secondary antibody and 3, 3' 
diaminobenzidine (DAB)/ H20 2 to visualize the bound anti­
bodies.
Histological and ultrastructural analysis. For routine histol­
ogy, tissues of mice (7-9- or 21-week-old, with age-matched 
controls) were fixed in 4% neutral buffered formalin or
Carnoy’s fluid (3 h), dehydrated and embedded in paraplast. 
Serial sections were stained with haematoxylin-eosin, periodic 
acid-Schiff and trichrome. For histological examination of 
semi-thin 1 |im sections of muscles of the neck region of 
homozygous and heterozygous mutant mice and correspond­
ing wild-type mice and ultrastructural investigations of 
extraocular muscles of a Tg26 and wild-type mouse the mus­
cles were dissected after fixation with 2% glutaraldehyde, post­
fixed in 1% osmic acid, dehydrated and embedded in epon 
812,
Biochemical characterisation of muscle fibres. For MHC
composition analysis muscles were isolated from a homozy­
gous Dmpk mutant mouse and a wild-type littermate (both 
females), and a Tg26 mouse and wild-type littermate (both 
males). MHC iso forms were separated from crude myosin 
extracts by gradient polyacrylamide gel electrophoresis and sil­
ver-stained gels were evaluated densitometrically26.
Intestinal transit testing. Small intestinal transit was tested on 
Tgl5 mice and wild-type littermates (2 males and 2 females of 
each, 8 weeks of age) as described49.
Electrophysiological analysis. In vitro electrophysiological 
measurements were done on diaphragms of three (two females 
and one male) Tg26 mice and wild-type mice each, all ten 
weeks of age. Muscle action potentials were invoked indirectly 
by electrical stimulation of the phrenic nerve; they were 
recorded intra- and extracellularly at 26 °C and 37 °C. Subse­
quently, the muscles were incubated in |i.-conotoxin to elimi­
nate muscle action potentials and endplate potentials and 
miniature endplate potentials were recorded intracellularly in 
muscle fibres at 28 °C as described50. For statistical analysis, 
the Student’s Rest was used. Before the mice were killed, an 
EMG search was made for myotonic runs in gastrocnemius 
muscles, using multiple needle movements under ether anes­
thesia.
ECG recording. After anesthesia with diethylether and after 
heparinization, hearts were excised from 3-, 8- and 13-m-old 
male Tg26 mice and 10-month-old-femalc Tg26 mice (3 
females) and from age-matched and sex-matched wild-type 
mice. The hearts were perfused at 37.5 °C as described for rat 
hearts33. ECG and pressure measurements were recorded 
simultaneously, at 0, 10 and 20 min after a stabilization period 
of 20 min and results were averaged.
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